Treatment News : Young Gay Men’s PrEP Study Shows Feasibility and Challenges

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » March 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


March 11, 2013

Young Gay Men’s PrEP Study Shows Feasibility and Challenges

A small study of pre-exposure prophylaxis (PrEP) among young gay men in Chicago was able with some struggle to recruit willing participants, but it found there was a marked discrepancy between their reported and their actual adherence to the medication, aidsmap reports. The study’s findings echo recent disappointing results from the VOICE trial among African women, which was unable to design PrEP modalities appealing enough to lead to high adherence among that population.

Publishing their results of their placebo-controlled study in the Journal of Acquired Immune Deficiency Syndromes, researchers studied 58 gay men, most of them African American, Hispanic or mixed race, between the ages of 18 and 22 who had all reported unprotected anal intercourse during the past year. They divided the men into three study groups: One received once-daily Truvada (tenofovir/emtricitabine); a second received a placebo; and a third received neither medication nor placebo, but, like the other groups, attended a clinic each month where they could receive safer-sex counseling in addition to health monitoring. All participants received a group-based behavioral intervention.

According to self-reports, participants adhered to PrEP at a rate of 72 percent for the first two months of the study and at 80 percent in the subsequent four months. Drug-level monitoring contradicted this assertion: Adherence began at about 50 to 60 percent in the first three months of the study and then declined to 20 percent at the six-month point. Due to the fact that the drug-level test could only detect the medication taken during the previous 48 hours, however, it is feasible that participants took PrEP intermittently and that the screens could have failed to detect total usage.

The study authors concluded that their results show that it is feasible to establish a study of gay youth taking PrEP and that group interventions given with counseling and HIV testing found high acceptance among the participants. However, their data draw into question how to better design such a study to encourage high adherence to PrEP.

To read the aidsmap story, click here.

Search: young gay men, pre-exposure prophylaxis, PrEP, Chicago, VOICE trail, aidsmap, Truvada, tenofovir, emtricitabine, self report.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.